

Butylphthalide for Cognitive Impairment in Elderly Patients With Focal Epilepsy

NCT07193277

Status	RECRUITING
Phase	Phase 4
Sponsor	First Affiliated Hospital of Wenzhou Medical University
Enrollment	220 participants

Key Eligibility Criteria

Inclusion (6)

- Age 60-85 years (inclusive)
- Diagnosed with focal epilepsy according to ILAE 2025 latest classification standards, with disease duration e2 years
- Currently receiving stable anti-seizure medication (ASM) treatment for e3 months, with good seizure control (monthly seizure frequency d4 times in the past 3 months)
- Cognitive impairment: Montreal Cognitive Assessment (MoCA) score 18-25 points (inclusive)
- Basic Chinese language comprehension and expression ability, able to cooperate with neuropsychological testing
- ... and 1 more (see full listing online)

Exclusion (9)

- Diagnosed with various types of dementia (including Alzheimer's disease, vascular dementia, etc.)
- Clear history of stroke with corresponding lesions on neuroimaging, or severe white matter lesions on brain MRI
- Other neurological diseases that may cause cognitive impairment (traumatic brain injury, encephalitis, hydrocephalus, etc.)
- Systemic diseases that may cause cognitive impairment (severe cardiac, hepatic, renal dysfunction, endocrine diseases, etc.)
- Current severe depression or other psychiatric diseases affecting cognitive assessment
- ... and 4 more (see full listing online)

Locations (1 total)

First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China